NEW YORK (GenomeWeb News) — US Genomics has signed an agreement with the Lahey Clinic to look at microRNAs and the development of urologic cancers, the company said today.
 
The company said that the Lahey Clinic will use US Genomics’ Trilogy 2020 molecule detection platform and its Direct miRNA assay to “develop more accurate prognoses” for patients suffering from bladder cancer and prostate cancer.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.